Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    strive anti-jcv
Show Display Options
Rank Status Study
1 Active, not recruiting Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: natalizumab

Indicates status has not been verified in more than two years